Meropenem Aptapharma (Meropenem Trihydrate)

Meropenem is a carbapenem antibiotic used to treat severe bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: achieves rapid bacterial eradication and resolution of intra‑abdominal sepsis.
• Complicated urinary tract infections: provides broad‑spectrum activity to clear resistant uropathogens.
• Bacterial meningitis: penetrates the cerebrospinal fluid to eliminate causative organisms.
• Severe community‑acquired or hospital‑acquired pneumonia: delivers bactericidal effect against resistant respiratory pathogens.
• Sepsis: offers immediate, wide‑range coverage to control systemic infection.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This blockade prevents cross‑linking of the cell wall, leading to osmotic instability and bacterial lysis. Its structure confers resistance to most β‑lactamases, allowing activity against a broad spectrum of Gram‑negative, Gram‑positive and anaerobic organisms. Consequently, meropenem achieves rapid bactericidal activity within hours of administration.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: transient skin erythema.
• Elevated liver enzymes: mild, reversible transaminase rise.
• Headache: occasional mild headache.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: risk of severe intestinal infection.
• Neutropenia: marked reduction in white blood cells.
• Renal dysfunction: acute kidney injury in susceptible individuals.

Prior to initiating meropenem therapy, clinicians should consider several precautionary measures to ensure safe use.

• Renal function assessment: adjust dose in patients with impaired clearance.
• Hepatic monitoring: observe liver function tests during prolonged therapy.
• History of seizures: avoid or monitor closely in individuals with prior convulsions.
• Concomitant nephrotoxic drugs: use caution when combined with other renal‑impacting agents.
• Allergy evaluation: verify no known hypersensitivity to β‑lactam antibiotics.
• Store at ambient temperature: keep vials in original packaging, protect from moisture and light.

Meropenem can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Valproic acid: may reduce serum levels, risking loss of seizure control.
• Probenecid: can increase meropenem concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: additive nephrotoxicity; monitor renal function.
• Loop diuretics: may enhance renal clearance, requiring dose adjustment.
• Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters.
• Oral contraceptives: potential reduction in effectiveness; advise alternative contraception.